Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A and Paratyphi B.

Antimicrobial agents and chemotherapy - 1 Sept 2010

Neupane Ganesh Prasad, Kim Dong-Min, Kim Sung Hun, Lee Bok Kwon

Abstract excerpt

Paratyphoid fever is considered an emerging systemic intracellular infection caused by Salmonella enterica serotypes Paratyphi A, B, and C. We performed in vitro time-kill studies on three clinical isolates of nalidixic acid-resistant Salmonella serotype Paratyphi (NARSP) with different concentrations of ciprofloxacin and cefotaxime to identify combinations of antibiotics with synergistic activity against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Proteins
Share to Cefotaxime

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ciprofloxacin

Share to Drug Resistance, Bacterial

Share to Drug Synergism

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Nalidixic Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 20566759
DOI: 10.1128/AAC.00988-09
PMCID: PMC2935016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A and Paratyphi B.PMID 20566759Read ↗

Mechanistic insights into synergy between nalidixic acid and tetracycline against clinical isolates of Acinetobacter baumannii and Escherichia coliSemantic proximity Read ↗

In vitro Synergistic Activity of Antimicrobial Combinations Against blaKPC and blaNDM-Producing Enterobacterales With blaIMP or mcr GenesSemantic proximity Read ↗

In vitro synergistic potentials of novel antibacterial combination therapies against Salmonella enterica serovar TyphimuriumSemantic proximity Read ↗

In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli.Semantic proximity Read ↗

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.Semantic proximity Read ↗

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Semantic proximity Read ↗

Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.Semantic proximity Read ↗

Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.